Misonix, Inc. (Nasdaq: MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products that enhance clinical outcomes, announced today that it has entered into an exclusive supply and distribution agreement with Gunze Limited for TheraGenesis® Bilayer Wound Matrix. TheraGenesis is a proprietary, FDA cleared, porcine tendon derived collagen wound matrix with a …
Press Release
Aktana, the pioneer in intelligent engagement for the life sciences industry, introduces its next-generation Contextual Intelligence Engine to optimize interactions with healthcare professionals (HCPs). Aktana’s Contextual Intelligence Engine combines advanced artificial intelligence technologies and human intelligence to align life sciences commercial teams’ engagement with HCPs across channels.
Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, today announced it has delivered more than 500,000 TMS treatments since the Company was founded in 2011.
ProSciento, Inc., a leading specialty clinical research organization (CRO) focused on non-alcoholic steatohepatitis (NASH), diabetes, obesity, and related metabolic diseases, announced today the closing of a growth financing from 1315 Capital, a healthcare investment firm that provides expansion and growth capital to commercial-stage healthcare services, medical technology and specialty therapeutics companies. SVB Leerink served as …
Innovative Health, Inc. today announced it has received FDA clearance for reprocessing the St. Jude Medical BRK Transseptal Needle and the Baylis Medical NRG Transseptal Needle. Innovative Health’s clearance to reprocess these market-leading transseptal needles is a milestone in single-use device reprocessing, as no other company is able to offer reprocessed transseptal needles and unlock additional …
Colorescience®, a leading dermatologist-recommended specialty skincare and cosmetics company, is pleased to announce the launch of a new brush-on powder sunscreen as part of their award-winning Total Protection™ portfolio. Well-regarded as the leader in innovative mineral sunscreen, Colorescience has applied their proprietary EnviroScreen™ Technology to formulate their market-leading sunscreen brush specifically for those with oily, …
Nutrition21, LLC (“Nutrition21“) has announced the conclusion of a dispute with MythLabs following MythLabs’ agreement to cease any further intellectual property (IP) infringement of Nutrition21’s ingredient Nitrosigine®. Nutrition21 discovered a product being sold in the marketplace, MythLabs Pump, that claimed to include the powerful NO booster Nitrosigine without a purchase and trademark license agreement. Upon …
Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX: GTMS) is pleased to announce the closing of its previously announced public offering (the “Offering”) of common shares of the Company (the “Offered Shares”). The Offering was made pursuant to an agency agreement (the “Agency Agreement”) entered into among Bloom Burton Securities Inc. and Clarus Securities Inc., …
Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX: GTMS) announced today that it has priced its previously announced overnight marketed offering (the “Offering”) of common shares of the Company (the “Offered Shares”). The Company intends to issue a minimum of 8,484,849 Offered Shares and a maximum of 10,909,091 Offered Shares at a price of C$1.65 …
Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX: GTMS) announced today that it has filed and been receipted for a preliminary short form prospectus (the “Preliminary Prospectus”) with securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, pursuant to National Instrument 44-101 Short Form Prospectus Distributions, in connection with a proposed …
Greenbrook’s Q1 2020 revenue is expected to be in the range of $11.3 million to $11.5 million (representing growth of approximately 70% as compared to revenue of $6.6 million in the first quarter of fiscal 2019 (“Q1 2019”)), and Q1 2020 Adjusted EBITDA loss is expected to be in the range of $1.6 million to …
Innovative Health, Inc. today announced the availability of three new informational web sessions, being held in early May, to help fill the learning gap left by the cancellation of this year’s Heart Rhythm Scientific Sessions. These sessions will educate administrators and clinicians on new and emerging opportunities for cost reductions through the reprocessing of advanced EP devices.